Skip to content

Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05691231
Enrollment
158
Registered
2023-01-19
Start date
2023-01-18
Completion date
2029-05-10
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Disc Disease, Degenerative Disc Disease

Brief summary

A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc at two levels in subjects who were enrolled in the IDE study (NCT03123549) and/or post approval study (NCT04980378).

Interventions

Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.

Sponsors

NuVasive
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site 2. Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study

Exclusion criteria

1. Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378) 2. Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)

Design outcomes

Primary

MeasureTime frameDescription
Clinical Composite Success Rate10 yearsIndividual success is defined as at least a 15 point improvement in Neck Disability Index (NDI) Score at 120 months compared with baseline, maintenance or improvement in neurologic status at 120 months compared with baseline, no additional surgical procedure at the index level within 120 months, and the absence of a serious adverse event classified as implant-associated or implant/surgical procedure-associated within 120 months. A subject must meet each criterion to be considered an overall study success. NDI scale is reported in a range from 0 - 100, with 0 consistent with best ability to function and 100 with worst ability to function.

Secondary

MeasureTime frameDescription
Percentage of subjects meeting MCID for neck and arm pain questionnaire for each of the following pain locations: neck pain, arm pain, left arm pain, right arm pain.10 yearsNeck and arm pain questionnaire, scale is reported in a range from 0 to 10, with 0 consistent with no pain and 10 with most pain
Motor status at each annual timepoint compared to baseline10 yearsA change of one or more grade levels in muscle strength will be regarded as clinically significant.
Sensory status at each annual timepoint compared to baseline10 yearsSensation will be graded as normal or abnormal (diminished or absent). Any changes from abnormal to normal or absent to diminished will be regarded as clinically significant improvement.
SF-36® Health Survey at each annual timepoint compared to baseline10 yearsThe SF-36 is a multipurpose survey with 36 questions. The questions were combined, scored and weighted to create mental and physical functioning and overall health-related quality of life. Higher scores indicate better outcomes. Scores range from 0-100.
Dysphagia Handicap Index1 (DHI) at each annual timepoint compared to baseline10 yearsDHI is scored from 0-100, with a higher score indicative of a less desirable outcome.
Percentage of subjects meeting the minimal clinically important difference (MCID) for NDI at each annual timepoint10 yearsNeck Disability Index; scale is reported in a range from 0-100, with 0 consistent with best ability to function and 100 worst ability to function.
Adjacent level disc degeneration (ALDD) at each annual timepoint will be compared to baseline10 yearsALDD is graded in accordance with definitions adapted from Kellgren and Lawrence: None; Doutbtful;Minimal;Moderate;Severe
Displacement or migration of the Simplify Disc at each annual timepoint will be compared to the post-op timepoint in the IDE study (NCT03123549)10 yearsDevice migration assesses significant movement of the implant postoperatively. Changes of \>3 mm will be considered significant due to the margin of error in radiographic determination of displacement distances.
Range of motion (ROM) at each annual timepoint compared to baseline10 yearsChanges in Global Range of Motion will be calculated by subtracting the range of motion measured at one time point from the baseline range of motion. Change in Global Range of Motion will be reported in units of degrees.
Rate of adverse events attributable to Simplify Disc, or use of additional NuVasive instruments, implants, or technologies at each annual timepoint10 yearsNumber of adverse events related to Simplify Disc or additional NuVasive products
Patient satisfaction and perceived effect at each annual timepoint10 yearsPatient questionnaire assessing satisfaction with treatment and perceived effect of treatment. Success for each satisfaction question will be defined as either a Definitely True or Mostly True response. Success for the perceived effect question will be defined as either a Completely Recovered, Much Improved, or Slightly Improved response.
Disc height at each annual timepoint will be compared to baseline10 yearsAverage disc height is calculated as the simple average of the anterior and posterior disc heights

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026